Paper Details

  1. Home
  2. Paper Details

Temozolomide salvage chemotherapy for recurrent anaplastic oligodendroglioma and oligo-astrocytoma.

Author: ChangJong Hee, GwakHo-Shin, HongYong-Kil, HwangJeong-Hyun, HwangSun-Chul, JungTae-Young, KangSeok-Gu, KimEalmaan, KimEun-Young, KimHae Yu, KimJeong Hoon, KimJin Wook, KimJuyoung, KimMin Su, KimSe-Hyuk, KimSeon-Hwan, KoYoung-Cho, LeeByeongil, LeeSeung Hoon, ParkBong Jin, ParkChul-Kee, SeolHo Jun, YeeGi Taek, YooHeon, YounJi Hye, YunHwan Jung

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Temozolomide (TMZ) chemotherapy showed an objective response rate of 24% in patients with recurrent anaplastic oligodendroglioma and anaplastic oligoastrocytoma.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To evaluate the efficacy of temozolomide (TMZ) chemotherapy for recurrent anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA). METHODS: A multi-center retrospective trial enrolled seventy-two patients with histologically proven AO/AOA who underwent TMZ chemotherapy fo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921276/

データ提供：米国国立医学図書館（NLM）

Temozolomide: A Promising Salvage Therapy for Recurrent Brain Tumors

This research delves into the complex and challenging landscape of brain tumor treatment, focusing on the effectiveness of temozolomide (TMZ) as a salvage therapy for recurrent anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA). It's like searching for an oasis in the vast desert of brain cancer, seeking a treatment that can provide respite and hope for patients facing this formidable disease.

Temozolomide's Potential: A Ray of Hope in the Desert

This study suggests that TMZ can be a valuable tool in the fight against recurrent brain tumors, offering a promising alternative to traditional therapies. It's like discovering a hidden spring of water in the desert, bringing renewed hope and energy to the journey. The research found that TMZ had a significant response rate, including complete responses in some cases, with tolerable side effects. These findings offer a glimmer of optimism for patients facing this challenging diagnosis.

Navigating the Challenges of Brain Tumor Treatment

Brain tumors are notoriously difficult to treat, and finding effective therapies is a constant challenge. This research offers valuable insights into the potential of TMZ as a salvage therapy, highlighting its ability to provide meaningful benefits for patients. It's like a guide leading us through the treacherous terrain of brain tumor treatment, offering a path toward improved outcomes.

Dr. Camel's Conclusion

This study brings a refreshing spring of hope to the arid landscape of brain tumor treatment. Temozolomide offers a promising salvage therapy for recurrent anaplastic oligodendroglioma and anaplastic oligoastrocytoma, providing a beacon of light in the fight against these challenging diseases. Further research is needed to fully understand TMZ's potential and refine treatment strategies, but the study offers a valuable starting point for navigating this challenging territory.

Date :
  1. Date Completed 2014-02-14
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24527191

DOI: Digital Object Identifier

PMC3921276

Related Literature

Article Analysis
・Side Effects of lomustine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.